Tumor necrosis factor-α differentially modulates CD44 expression in ovarian cancer cells

Molecular Cancer Research

Volumn 4, Issue 8, 2006, Pages 511-520

  Muthukumaran, Neelakandan ^a   Miletti González, Karl E ^a   Ravindranath, Abhilash K ^a   Rodríguez Rodríguez, Lorna ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGENIC MODULATION; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD44; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; LAMININ; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEOGLYCANS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748425772     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0232     Document Type: Article

References (31)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
3. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
4. Hassan MI, Kassim SK, Saeda L, Laban M, Khalifa A. Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-α (TNF-α) release from ovarian tissue. Anticancer Res 1999;19:5657-62.
5. Xiao CW, Van X, Li Y, Reddy SA, Tsang BK. Resistance of human ovarian cancer cells to tumor necrosis factor α is a consequence of nuclear factor κB-mediated induction of Fas-associated death domain-like interleukin-1β-converting enzyme-like inhibitory protein. Endocrinology 2003;144:623-30.
6. Powell CB, Scott JH, Collins JL. Comparison of TNFα and TNFβ cytolytic mechanisms in human ovarian and cervical carcinoma cell lines. Gynecol Oncol 1998;71:258-65.
7. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001;61:3493-500.
8. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
9. Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993;184:47-63.
10. Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998;273:338-43.
11. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992;89:12160-4.
12. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
13. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
14. Speiser P, Wanner C, Breitenecker G, Kohlberger P, Kainz C. CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. Anticancer Res 1995; 15:2767-9.
15. Rodriguez-Rodriguez L, Sancho-Torres I, Leakey P, et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol Oncol 1998;71: 223-9.
16. Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol 2003;20:255-63.
17. Cannistra SA, Abu-Jawdeh G, Niloff J, et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 1995;13:1912-21.
18. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321:265-79.
19. Stadlmann S, Raffeiner R, Amberger A, et al. Disruption of the integrity of human peritoneal mesothetium by interleukin-1β and tumor necrosis factor-α. Virchows Arch 2003;443:678-85.
20. Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of etanercept, a tumor necrosis factor-α inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005;23:5950-9.
21. Speciale L, Ruzzante S, Calabrese E, et al. 1-40 β-Amyloid protein fragment modulates the expression of CD44 and CD71 on the astrocytoma cell line in the presence of IL1β and TNFα. J Cell Physiol 2003;196:190-5.
22. Levesque MC, Haynes BF. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-α and is inhibited by IL-4 and IL-13. J Immunol 1997;159:6184-94.
23. Gee K, Kozlowski M, Kumar A. Tumor necrosis factor-α induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 2003;278:37275-87.
24. Gee K, Lim W, Ma W, et al. Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-α in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression. J Immunol 2002;169:5660-72.
25. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006;13:465-77.
26. Knupfer MM, Knupfer H, Van Gool S, Domula M, Wolff JE. Interferon γ inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro. Cytokine 2000;12:409-12.
27. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62: 6864-9.
28. Miletti-González K, Chen S, Muthukumaran N, et al. The CD44 receptor interacts with P-glycoprotein (P-gp) to promote cell migration and invasion in cancer. Cancer Res 2005;65:6660-7.
29. Lokeshwar VB, Iida N, Bourguignon LY. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996;271:23853-64.
30. Knupfer MM, Poppenborg H, Hotfilder M, Kuhnel K, Wolff JE, Domula M. CD44 expression and hyaluronic acid binding of malignant glioma cells. Clin Exp Metastasis 1999;17:71-6.
31. + exchanger (NHE1) creates acidic microenvironment leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004;25:26991-7007.